The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Purpose
To assess mean change in visual acuity (VA) overall and stratified by baseline VA after 1 and 2 years’ treatment with aflibercept in a real‐life setting.
Methods
This was an observational cohort study using nationwide data from the Swedish Macula Register. Treatment‐naïve patient eyes with wet age‐related macular degeneration and prescribed aflibercept from January 2013 to December 2014...
The current body of evidence on the efficacy and safety of aflibercept for age‐related macular degeneration (AMD) is steadily growing as large clinical trials and observational studies are continually completed. Our aim was to analyse 1‐year visual acuity (VA) outcomes in response to aflibercept therapy and identify factors affecting treatment response using evidence generated from a pooled analysis...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.